---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-101394"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-09-18T23:59:59+00:00"
generated_at: "2026-06-10T14:24:35.198345+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eloxx reports positive kidney biopsy results from Phase 2 ELX-02 trial in Alport syndrome

## Summary
- Three patients showed improvement in foot process effacement on TEM kidney biopsies after 8 weeks of ELX-02 treatment.
- Patient 4401-02 achieved remission based on Urine-Protein Creatine Ratio (UPCR).
- Patient 4402-01 showed wider intact foot process areas, though pre/post comparison was limited.
- Company to seek FDA alignment on pivotal trial design and Breakthrough Therapy Designation for ELX-02.

## SEC filing metadata
- accession: 0001104659-23-101394
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923101394/0001104659-23-101394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923101394/tm2326310d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-101394
- JSON: https://secwatch.observer/filing/0001104659-23-101394.json
- Plain text: https://secwatch.observer/filing/0001104659-23-101394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.